R. T. Owen, “Milnacipran Hydrochloride: Its Efficacy, Safety and Tolerability Profile in Fibromyalgia Syndro- me,” Drugs Today, Vol. 44, No. 9, 2008, pp. 653-660. http://dx.doi.org/10.1358/dot.2008.44.9.1256003
 C. U. Pae, D. M. Marks, M. Shah, C. Han, B. J. Ham, A. A. Patkar and P. S. Masand, “Milnacipran: Beyond a Role of Antidepres-sant,” Clinical Neuropharmacology, Vol. 32, No. 6, 2009, pp. 355-363. http://dx.doi.org/10.1097/WNF.0b013e3181ac155b
 A. Nakagawa, N. Watanabe, I. M. Omori, C. Barbui, A. Cipriani, H. McGuire, R. Churchill and T. A. Furukawa, “Milnacipran versus Other Antidepressive Agents for De- pression,” The Cochrane Library, 2009. doi:10.1002/14651858.CD006529.pub2
 J. C. Branco, S. Perrot, G. Bragee, et al., “The PTPN22* C1858T Functional Polymorphism Is Associated with Susceptibility to Inflammatory Polyarthritis but Neither This Nor Other Variants Spanning the Gene Is Associated with Disease Outcome,” Annals of the Rheumatic Diseases, 2008, Vol. 67, pp. 251-255.
 M. Lecoeur-Lorin, R. Delépée, J. P. Ribet and P. J. Morin, “Chiral Analysis of Milnacipran by a Nonchiral HPLC— Circular Dichroism: Improvement of the Linearity of Dichroic Response by Temperature Control,” Journal of Se- paration Science, Vol. 31, No. 16-17, 2008, pp. 3009- 3014.
 C. Puozzo, C. Filaquier and G. J. Zorza, “Determination of Milnacipran, a Serotonin and Noradrenaline Reuptake Inhibitor, in Human Plasma Using Liquid Chromato-graphy with Spectrofluorimetric Detection,” Journal of Chro- matography B, Vol. 806, No. 2, 2004, pp. 221-228.
 C. Puozzo, N. Pozet, D. Deprez, P. Baille, H. L. Ung and P Zech, “Pharmacokinetics of Milnacipran in Renal Impairment,” Eu-ropean Journal of Drug Metabolism and Pharmacokinetics, Vol. 23, No. 2, 1998, pp. 280-286.
 M. Srinivasa Rao, V. Sivaramakrishna, S. V. M. Vardhan and D. Ramachandran “A Validated Rp-Hplc Method for the Estimation of Milnacipran in Tablet Dosage Forms,” International Journal of Chem Tech Research, Vol. 3, No. 3, 2011, pp. 1501-1505.
 P. J. Mehta, et al., “Development and validation of RP-HPLC Method for determination of Milnacipran Hydrochloride in pharmaceutical formulations,” International Journal of Phar-macy and Pharmaceutical Sciences, Vol. 2, No. 2, 2010, pp. 137-141.
 C. L. Dias, et al., “Comparative Validation Study to Assay Milnacipran Hydrochloride in Capsules by a Stability-Indicating LC and a Second Order Derivative UV Spectroscopic Methods,” Pharmaceutica Analytica Acta, Vol. 1, No. 2, 2010, pp. 1-5.
 M. Bakshi and S. Singh, “Development of Validated Stability-Indicating Assay Methods—Critical Re-view,” Jour- nal of Pharmaceutical and Biomedical Analysis, Vol. 28, No. 6, 2002, pp. 1011-1040. doi:10.1016/S0731-7085 (02)00047-X